Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
durvalumab
Biotech
AstraZeneca posts rare cancer win for treme, beating Nexavar
After multiple flops, AstraZeneca has reported improved survival in a phase 3 checkpoint inhibitor combination study in liver cancer patients.
Nick Paul Taylor
Oct 15, 2021 8:15am
Sanofi-Merck and AstraZeneca-Arcus team up for cancer combos
Oct 29, 2020 8:30am
Israeli biotech NeoTX lands $45M series C for combo cancer test
Feb 19, 2020 7:15am
AstraZeneca's I-O combo fails crucial Mystic trial in lung cancer
Jul 27, 2017 3:45am
AstraZeneca pulls PD-L1 combo test, RSV candidate
Feb 3, 2017 3:22am
